Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?

J Clin Oncol. 2007 Oct 1;25(28):4506-7; author reply 4508. doi: 10.1200/JCO.2007.13.0401.
No abstract available

Publication types

  • Comment
  • Comparative Study
  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / economics*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cost-Benefit Analysis
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / economics
  • Drug Costs*
  • Erlotinib Hydrochloride
  • Gemcitabine
  • Humans
  • Pancreatic Neoplasms / drug therapy*
  • Quality-Adjusted Life Years*
  • Quinazolines / administration & dosage
  • Quinazolines / adverse effects
  • Quinazolines / economics
  • Survival Analysis
  • United States

Substances

  • Quinazolines
  • Deoxycytidine
  • Erlotinib Hydrochloride
  • Gemcitabine